Breast Cancer Literature Review

Breast Cancer Literature Review-21
Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer diagnoses.As novel targets and therapies for TNBC emerge, a comprehensive overview of the current landscape of evidence on the approved or developing treatment options was needed.We followed Cochrane guidelines for systematic literature reviews (SLR).

Tags: Med School EssaysSkeletal System AssignmentEssays On Air And Space Power Vol. IiLesson Plans Descriptive Essay PromptsThesis Statement Vs Thesis QuestionCritical Essay Cry Beloved Country

Overall survival (n = 32) and progression-free survival (n = 30) were the most commonly reported efficacy outcomes. Targeted therapies, followed by chemotherapy in forms of combinations of 2 or more subclasses, composed most trials in TNBC, with immunotherapy being rarely used thus far.

The trials were mainly conducted in metastatic or advanced setting, followed by neoadjuvant and adjuvant settings.

Find out more about the Kindle Personal Document Service.

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies.

A search from January 2003 to July 2018 was performed on MEDLINE®, Embase, the Cochrane Central Database of Controlled Trials, and the US and European clinical trials registries.

Conference proceedings from ASCO, ESMO, and SABCS covering the period from 2016 to end of 2018 were also reviewed. Eighty-nine publications corresponding to 77 unique trials met the eligibility criteria for this review. The 72 RCTs and 5 comparative non-RCTs were predominantly open-label phase 2 or 3 trials. Then enter the ‘name’ part of your Kindle email address below. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi.‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.Immune checkpoint inhibitors, including nivolumab, atezolizumab, durvalumab, and pembrolizumab, were evaluated in 5 trials. Targeted therapies, primarily VEGF inhibitors (n = 12) and PARP inhibitors (n = 7), were evaluated in 40 trials. Case-only studies and clinical trials were excluded.Our study revealed that the majority of African BC genetic studies remain restricted to the investigation of BRCA1 and BRCA2 genes and differences in their mutations spectrum.It includes a total of 14 studies using large databases and 27 other studies using qualitative and quantitative methods.In our review of this literature, we identified four broad themes, including access to treatment and treatment type, medical providers and health information, psychosocial adjustment and coping, and social support and psychological support services.


Comments Breast Cancer Literature Review

The Latest from ©